The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Sam M., Ansari, Azim M., Frater, John, Klenerman, Paul, Dunachie, Susanna, Barnes, Eleanor, Ogbe, Ane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765363/
https://www.ncbi.nlm.nih.gov/pubmed/36539527
http://dx.doi.org/10.1038/s41577-022-00809-x
_version_ 1784853468629958656
author Murray, Sam M.
Ansari, Azim M.
Frater, John
Klenerman, Paul
Dunachie, Susanna
Barnes, Eleanor
Ogbe, Ane
author_facet Murray, Sam M.
Ansari, Azim M.
Frater, John
Klenerman, Paul
Dunachie, Susanna
Barnes, Eleanor
Ogbe, Ane
author_sort Murray, Sam M.
collection PubMed
description Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as a likely source of this cross-reactivity. However, the role of such cross-reactive responses in the outcome of SARS-CoV-2 infection and vaccination is currently unclear. Here, we review evidence regarding the impact of pre-existing humoral and T cell immune responses to outcomes of SARS-CoV-2 infection and vaccination. Furthermore, we discuss the importance of conserved coronavirus epitopes for the rational design of pan-coronavirus vaccines and consider cross-reactivity of immune responses to ancestral SARS-CoV-2 and SARS-CoV-2 variants, as well as their impact on COVID-19 vaccination.
format Online
Article
Text
id pubmed-9765363
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97653632022-12-21 The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses Murray, Sam M. Ansari, Azim M. Frater, John Klenerman, Paul Dunachie, Susanna Barnes, Eleanor Ogbe, Ane Nat Rev Immunol Perspective Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as a likely source of this cross-reactivity. However, the role of such cross-reactive responses in the outcome of SARS-CoV-2 infection and vaccination is currently unclear. Here, we review evidence regarding the impact of pre-existing humoral and T cell immune responses to outcomes of SARS-CoV-2 infection and vaccination. Furthermore, we discuss the importance of conserved coronavirus epitopes for the rational design of pan-coronavirus vaccines and consider cross-reactivity of immune responses to ancestral SARS-CoV-2 and SARS-CoV-2 variants, as well as their impact on COVID-19 vaccination. Nature Publishing Group UK 2022-12-20 2023 /pmc/articles/PMC9765363/ /pubmed/36539527 http://dx.doi.org/10.1038/s41577-022-00809-x Text en © Springer Nature Limited 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Perspective
Murray, Sam M.
Ansari, Azim M.
Frater, John
Klenerman, Paul
Dunachie, Susanna
Barnes, Eleanor
Ogbe, Ane
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title_full The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title_fullStr The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title_full_unstemmed The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title_short The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
title_sort impact of pre-existing cross-reactive immunity on sars-cov-2 infection and vaccine responses
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765363/
https://www.ncbi.nlm.nih.gov/pubmed/36539527
http://dx.doi.org/10.1038/s41577-022-00809-x
work_keys_str_mv AT murraysamm theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT ansariazimm theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT fraterjohn theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT klenermanpaul theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT dunachiesusanna theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT barneseleanor theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT ogbeane theimpactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT murraysamm impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT ansariazimm impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT fraterjohn impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT klenermanpaul impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT dunachiesusanna impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT barneseleanor impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses
AT ogbeane impactofpreexistingcrossreactiveimmunityonsarscov2infectionandvaccineresponses

Ejemplares similares